On May 20, 2024, the U.S. Food and Drug Administration (FDA) approved Yesafili™ (aflibercept-jbvf) and Opuviz™ (aflibercept-yszy) as interchangeable biosimilars for Eylea® (aflibercept). Both biosimilars are approved for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic neuropathy. Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor that works by preventing unusual blood vessel growth in the eye. Through this blockage of VEGF, aflibercept reduces damage to the retina and helps preserve vision. Depending on the state pharmacy laws, interchangeable biosimilars may be substituted for the reference product without requiring prescriber consultation. Comparative data demonstrated that both products showed a high similarity to Eylea® and had no clinically meaningful differences in safety and effectiveness. Side effects seen with Yesafili™ and Opuviz™ are similar to Eylea®, including eye pain, cataract, broken blood vessels in the eye, floaters and increased eye pressure. The approval of Yesafili™ and Opuviz™ will increase accessibility of this treatment at a potentially lower cost. The exact timeframe when Yesafili™ and Opuviz™ will become available is still unknown due to ongoing litigation.